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Atherosclerosisapolipoprotein B (apoB) on cell viability, we used lipid-free apoB as a model for
denatured apoB. Lipid-free apoB had cytotoxicity to J774 macrophages, CHO cells and HepG2 cells, whereas
apoB bound to low density lipoprotein (LDL) and lipid-free apolipoprotein A-I had no effect on cell viability.
Lipid-free apoB induced apoptosis in J774 macrophages assessed by caspase-3 activation and annexin V
binding. LDL receptor, heparan sulfate proteoglycans, and class A scavenger receptor were involved in the
binding/uptake of lipid-free apoB, but lipid-free apoB binding/uptake by the cells did not correlate with
cytotoxicity. Lipid-free apoB disrupted the lipid bilayer of large unilamellar vesicles containing calcein. We
evaluated the interaction between apoB and cellular membrane bymonitoring the change in intracellular Ca2+
concentration using Fura-2, and found that lipid-free apoB rapidly disrupted the cellular membrane in the
absence or presence of the inhibitors for cellular binding/uptake mediated by the receptors. Therefore, it is
suggested that lipid-free apoB induces cell death by disturbance of the plasmamembrane. In addition to other
lipid component in modiﬁed LDL, apoB itself has an ability to induce apoptosis and plays a crucial role in the
development of atherosclerotic lesions.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe subendothelial retention of atherogenic lipoproteins, low
density lipoprotein (LDL) and triglyceride-rich lipoproteins is a critical
step in the initiation of atherosclerosis. Denatured LDL is accumulated
abundantly in atherosclerotic lesions [1,2]. This accumulation of
denatured LDL induces the apoptosis of vascular endothelial cells and
monocyte-derived macrophages [3,4]. Numerous studies have identi-
ﬁed apoptosis as a prominent feature of atherosclerosis [5–8]. All cell
types present in atherosclerotic plaques, including endothelial cells,
smooth muscle cells, lymphocytes and macrophages, are known to
undergo apoptosis. It has been suggested that macrophage apoptosis
in early lesions decreases macrophage burden and slows lesion
progression [9–11]. On the other hand, macrophage apoptosis in late
lesions causes necrotic core formation, which may promote inﬂam-
mation, plaque rupture, and thrombosis [11]. Therefore, the macro-
phage apoptosis is a crucial determinant of lesion development.
In early atherosclerotic lesions, even before atheroma appears,
symptomatic patients have signiﬁcantly more arterial apolipoproteinsity lipoprotein; NaDC, sodium
apoB bound to LDL; apoA-I,
, class A scavenger receptor;
al bovine serum; LDH, lactate
UV, large unilamellar vesicles;
-tetraacetic acid
81 75 753 4601.
akano).
ll rights reserved.B (apoB) deposits than patients without cardiovascular events, and
large amounts of apolipoproteins are found in advanced athero-
sclerotic lesions [12]. ApoB is a 4536-residue polypeptide that
comprises the major protein component of very low density
lipoprotein and its metabolite LDL. ApoB has a particular role in
maintaining the structural integrity of LDL particles and controlling
their interaction with LDL receptors [13]. The peak size of human LDL
can be separated into two phenotypes: large buoyant LDL of 24–25 nm
and small dense LDL of 18–20 nm (sdLDL) [14]. Although arguments
have been raised for the casual relationship between sdLDL and
cardiovascular disease, the predominance of sdLDL has been indicated
as an emerging cardiovascular risk factor and a consistent character-
istic of familial combined hyperlipidemia [15,16]. Recently, a low
resolution model of apoB was revealed by small angle neutron
scattering in combination with advanced shape reconstitution algo-
rithms showing that the lipid-free protein adopts an expanded curved
shape composed of distinct domains connected ﬂexible regions [17].
The radius of gyration of 15 nm implies that lipid-free or lipid-poor
apoB possibly constitutes a part of sdLDL.
Delipidated apoB is insoluble in aqueous buffers in the absence of
detergents or high concentrations of denaturants [18]. A LDL particle
contains a single apoB molecule together with about 3000 lipid
molecules. Walsh and Atkinson developed a method to delipidate and
purify apoB on LDL by using 10 mM sodium deoxycholate (NaDC) [19].
In this study, we investigated the cytotoxic effect of lipid-free apoB
(free apoB) solubilized with NaDC, as a model for denatured apoB, and
compared it with apoB bound to LDL (LDL-apoB) and lipid-free,
exchangeable apolipoprotein A-I (apoA-I). We also examined the
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gated the interaction of free apoB with cellular membrane to clarify its
cytotoxic mechanism.
2. Materials and methods
2.1. Materials
Human apoA-I was purchased from Chemicon International
(Tamecula, CA). Human plasma LDL (d=1.02–1.063) was obtained
from Calbiochem (San Diego, CA). Heparin, bovine serum albumin
(BSA), egg yolk phosphatidylcholine (PC), EGTA and thapsigarginwere
obtained from Sigma Chemical Co. (St. Louis, MO). Rat anti-mouse
class A scavenger receptor (SRA) (2F8) was purchased from Serotec,
Inc. (Raleigh, NC) and mouse anti-murine CD36 IgA (clone 63) was
from Cascade Biosciences (Winchester, MA). Calcein and Fura-2-AM
were purchased from Dojindo Laboratories (Kumamoto, Japan). All
other chemicals used were of the highest reagent grade.
2.2. Free apoB
Human free apoB, provided by Chemicon, was puriﬁed from
plasma LDL isolated by density gradient ultracentrifugation followed
by size exclusion chromatography in 10 mM NaDC, 50 mM NaCl, and
50 mM Na2CO3 (pH 10). The stock solution of free apoB (∼1.5 mg
protein/ml in 10 mM NaDC) was stored at 4 °C. Because free apoB
was puriﬁed from plasma LDL, free apoB was mainly apoB100 but
not apoB48. Most of free apoB showed a major high-molecular-mass
band (N500 kDa) on a 5–20% SDS-PAGE gel detected by 0.1%
Coomassie Brilliant Blue R-250 staining, whereas a minor broad band
(200–500 kDa) was also shown on the gel, probably due to
incomplete denaturation or cleavage of a small number of apoB.
The apoB preparation did not contain detectable amount of
phospholipids, triglycerides, free cholesterol or cholesteryl ester
tested by the enzymatic assay kits purchased from Wako Pure
Chemical Industries (Osaka, Japan), indicating that the apoB
solubilized in NaDC was free of lipid, whereas the concentrations
of phospholipids, triglycerides, free cholesterol and cholesteryl ester
in the LDL-apoB preparation were 1.26, 0.389, 0.959 and 2.51 μmol/
mg protein, respectively. The apoB concentration was determined by
the method of Lowry.
2.3. CD spectral measurements
CD spectra of LDL-apoB and free apoB in 0.5 mM NaDC were
recorded on a JASCO J-820 spectropolarimeter, using a 0.1 cm quartz
cuvette, in the peptidic region (200–250 nm). Free apoB (20 μg/ml)
was solubilized in 0.5 mM NaDC. To increase the signal-to-noise
ratio, eight spectra were averaged for each measurement, and the
blank was subtracted. The cell holder compartment was thermo-
statically maintained at 37 °C. The spectra were analyzed for the
secondary structure contents using the software accompanying the
spectropolarimeter.
2.4. Cell cultures
J774 macrophages and HepG2 cells were grown in a humidiﬁed
incubator (5% CO2) at 37 °C in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), L-glutamine, penicillin, and streptomycin. CHO cells
were grown in a humidiﬁed incubator (5% CO2) at 37 °C in Ham's F12
supplemented with 10% heat-inactivated FBS, L-glutamine, penicillin,
and streptomycin. The FBS was changed to 1% BSA 15 min before each
experiment. Experiments were performed in DMEM containing 1%
BSA for J774 macrophages and HepG2 cells, and Ham's F12 containing
1% BSA for CHO cells.2.5. Cell viability assays
Cells were incubated for 6 h with various concentrations of free
apoB, LDL-apoB or apoA-I in the presence of 0.5 mM NaDC. After
incubation, the cells were chilled on ice and washed twice with cold
Hepes buffer containing 0.2% BSA and then washed twice with cold
Hepes buffer alone. The cells were then dissolved in 0.2% Triton X-100.
Cell viability was estimated by measuring the lactate dehydrogenase
(LDH) activity in the media and total cells using a CytoTox 96 Non-
Radioactive Cytotoxicity Assay Kit purchased from Promega (Madison,
WI). The LDH-mediated conversion of the tetrazolium salt into the red
formazan product was measured at 490 nm. The fraction of LDH
release was an index of irreversible injury or necrosis. %LDH
release=LDH activity in media/(LDH activity in media+LDH activity
in total cells)×100%.
2.6. Differential interference-contrast microscopy
Cells grown on culture dishes were incubated for 6 h with 0.5 mM
NaDC in the presence or absence of free apoB, LDL-apoB or apoA-I, and
washed twice with cold Hepes buffer containing 0.2% BSA and with
cold Hepes buffer. The cells were then viewed with an Olympus IX70
microscope.
2.7. Quantiﬁcation of caspase-3 activity
J774 macrophages were incubated for 3 h with 0.5 mM NaDC in
the presence or absence of 20 μg/ml free apoB. After incubation, the
cells were chilled on ice and washed twice with cold Hepes buffer
containing 0.2% BSA and then washed twice with cold Hepes buffer
alone. The cells were then dissolved in 0.2% Triton X-100. The
caspase-3 activity in the cell lysate was measured using Caspase-3
Fluorometric Assay Kit purchased fromBioVision, Inc. (Mountain View,
CA). The substrate for the assay was Ac-Asp-Glu-Val-Asp-[7-amino-
4-triﬂuoromethyl coumarin]. Cleavage of the substrate by caspase-3
resulted in the emission of a ﬂuorescent signal. The ﬂuorescence
intensity was measured using a ﬂuorescence microplate reader
equipped with a 390-nm excitation ﬁlter and a 535-nm emission
ﬁlter.
2.8. Annexin V-ﬂuorescein and propidium iodide (PI) staining
J774 macrophages grown on culture dishes were incubated for
6 h with 0.5 mM NaDC in the presence or absence of 20 μg/ml free
apoB, and washed twice with cold Hepes buffer containing 0.2% BSA
and with cold Hepes buffer. Phosphatidylserin externalization was
assayed by binding of ﬂuorescein-labeled annexin V using Annexin-
V-FLUOS Staining Kit obtained from Roche Applied Science (Penz-
berg, Germany) according to the manufacturer's instructions. Brieﬂy,
cells were incubated with annexin V-ﬂuorescein in a Hepes buffer
containing PI for 15 min at room temperature. Cells were
immediately viewed with an Olympus IX70 inverted ﬂuorescence
microscope. Eight ﬁelds of cells for each condition (∼1200 cells)
were counted.
2.9. ApoB binding/uptake assays
Free apoB and LDL-apoB were labeled using Fluorescein Labeling
Kit-NH2 provided by Dojindo. The cells were incubated with
ﬂuorescein-labeled free apoB or LDL-apoB at 37 °C for 2 h in the
presence of 0.5 mM NaDC. After incubation, the cells were chilled on
ice and washed twice with cold Hepes buffer containing 0.2% BSA and
then washed twice with cold Hepes buffer alone. The cells were
dissolved in 0.2% Triton X-100. The amount of apoB in the cell lysate
was determined from the ﬂuorescence intensity of ﬂuorescein
(excitation 490 nm, emission 520 nm) measured with a Hitachi
Table 1
The secondary structure contents of LDL-apoB and free apoB
α-Helix β-Sheet β-Turn Random coil
(%)
LDL-apoB 41.3±0.8 19.4±3.4 24.5±2.1 14.7±1.3
Free apoB 31.0±1.3 25.5±2.4 18.2±2.6 25.4±0.8
The CD spectra in Fig. 1A were used to determine the contents of secondary structures.
Each data represents the mean±S.D. of three independent measurements.
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measured by the method of Lowry was determined to correct the
apoB binding/uptake. The 2 h incubation of J774 macrophages with
10 μg/ml free apoB at 37 °C had no effect on the cell viability and the
content of cellular protein.
2.10. Fluorescence leakage assay
For leakage measurements, large unilamellar vesicles (LUV)
containing calcein were prepared by the extrusion method. A thin
ﬁlm obtained by evaporating the lipid chloroform solution was left
under vacuum overnight to remove residual organic solvent, and was
subsequently hydrated with 10mM Tris–HCl buffer, pH 7.4, containing
1 mM EDTA and 70 mM calcein. After ﬁve rounds of freeze-thawing,
the lipid suspension was extruded through a 100-nm pore size
polycarbonate ﬁlter. Untrapped dye was removed by gel ﬁltration
through a Bio-Rad A-50 m column eluted with the buffer. The
phospholipid concentration was determined according to the proce-
dure of Bartlett [20]. Free apoB, LDL-apoB or apoA-I was added to the
calcein-containing LUV in the presence of 0.5 mM NaDC, and the
ﬂuorescence intensity of calcein (excitation 490 nm, emission 520 nm)
was monitored at 37 °C. The percent leakage of calcein was
determined using the ﬂuorescence intensity corresponding to 100%
leakage obtained in the presence of 1% Triton X-100.Fig. 1. CD spectra of LDL-apoB and free apoB. (A) CD spectra of LDL-apoB (gray line) and
free apoB (black line) in the presence of 0.5 mM NaDC were measured at 37 °C. Each
sample contained 20 μg/ml apoB. Average results are from three independent
measurements for each sample. (B) The CD difference spectrum between LDL-apoB
and free apoB, (LDL-apoB)− (free apoB), were determined from the CD spectra in panel A.2.11. Intracellular Ca2+ measurements
J774 cells were removed from culture dishes by pipetting and
centrifuged at 1200 rpm for 10 min. After the medium was removed,
the cells were suspended and adjusted to 1.0×106–107 cells/ml in
DMEM. After centrifugation, the DMEM was removed again, and the
cells were suspended in Hepes buffer containing 3.5 μM Fura-2-AM
and 1.8 mM CaCl2, and incubated for 60 min at 37 °C. The cells were
then washed three times with Hepes buffer and ﬁnally suspended in
Hepes buffer containing either 1.8 mM CaCl2 or 0.3 mM EGTA. Free
apoB, LDL-apoB or apoA-I was added to the cell suspension, and the
ﬂuorescence intensity was monitored at 510 nm with alternative
excitation at 340 and 380 nm using a Hitachi F-2500 spectro-
ﬂuorometer at 37 °C. The ratio of the ﬂuorescence intensity at
excitation wavelengths of 340 and 380 nm corresponds to the
intracellular Ca2+ concentration.
2.12. Statistical analysis
The statistical signiﬁcance of differences betweenmean values was
analyzed using the non-paired t-test. Multiple comparisons were
performed using the Dunnet test or Bonferroni test following ANOVA.
Differences were considered signiﬁcant at Pb0.05. Unless indicated
otherwise, results are given as mean±S.E. (n=3).
3. Results
3.1. CD spectrum of free apoB
To examinewhether the solubilization of free apoB by NaDC affects
the secondary structure, CD spectra of free apoB and LDL-apoB were
recorded and evaluated. Because free apoB was solubilized in NaDC,
the same amount of NaDCwas added to LDL-apoB. The CD spectrum of
LDL-apoB was not affected by the presence of 0.5 mM NaDC (data not
shown). Fig. 1A shows the CD spectra of LDL-apoB and free apoB in the
presence of 0.5 mM NaDC. The CD spectrum of free apoB was slightly
different from that of LDL-apoB. Fig. 1B depicts the difference
spectrum between the CD of LDL-apoB and free apoB, which are
closely similar to the CD difference spectrum between intact and
heated LDL reported by Jayaraman et al. [21]. The analysis of the CD
signal revealed that the secondary structure of LDL-apoB was
characterized by a large content of α-helix and smaller amount of
β-sheet, β-turn and random coil (Table 1), in agreement with previous
studies [17,22,23]. The α-helix content of free apoB was lower than
that of LDL-apoB, while the content of random coil was higher.
However, the overall secondary structure of free apoB was highly
conserved, suggesting the solubilization of free apoB by NaDC may
lead to only partial unfolding of the secondary structure in apoB rather
than global protein unfolding as shown in oxidized LDL or electro-
negative LDL [22,24–26].
3.2. Cytotoxic effects induced by free apoB
We investigated the effect of NaDC on the cell viability, because
NaDC is required to solubilize free apoB in the medium. NaDC, at
concentrations below 0.5 mM, had no effect on the LDH release from
2597S. Morita et al. / Biochimica et Biophysica Acta 1778 (2008) 2594–2603J774 macrophages, CHO cells and HepG2 cells (Fig. 2A–C). However,
above 1 mM, NaDC signiﬁcantly increased the LDH release from three
types of cells.
To study the cytotoxic effects of free apoB, J774 macrophages, CHO
cells and HepG2 cells were incubated with various concentrations of
free apoB, LDL-apoB or apoA-I for 6 h, and then LDH release from the
cells was measured. To make the effect of NaDC constant, the NaDC
concentration was kept the same (0.5 mM) at all free apoB, LDL-apoB
and apoA-I concentration. Surprisingly, free apoB induced LDH
release from J774 macrophages in a concentration-dependent
manner (Fig. 3A). The LDH release was signiﬁcantly increased by at
least 5 μg/ml free apoB. When these cells were incubated with LDL-
apoB or apoA-I, they did not exhibit any increase in LDH release.Fig. 2. LDH release from cells induced by NaDC. J774 macrophages (A), CHO cells (B) or
HepG2 cells (C) were incubated with NaDC at the indicated concentrations for 6 h
at 37 °C. Each point represents the mean±S.E. of three measurements. ⁎Pb0.05,
signiﬁcantly different from the LDH release in the absence of NaDC.
Fig. 3. LDH release from cells induced by free apoB. J774 macrophages (A), CHO cells (B)
or HepG2 cells (C) were incubated with 0.5 mM NaDC in the presence of free apoB
(closed circles), LDL-apoB (open circles) or apoA-I (open triangles) at the indicated
concentrations for 6 h at 37 °C. Each point represents the mean±S.E. of three
measurements. ⁎Pb0.05, signiﬁcantly different from the LDH release in the absence of
free apoB, LDL-apoB and apoA-I.Similar results were obtained in CHO cells and HepG2 cells (Fig. 3B
and C). HepG2 cells were more resistant to both free apoB and NaDC
than J774 macrophages and CHO cells (Figs. 2 and 3).
J774 macrophages incubated for 6 h in the presence of 0.5 mM
NaDC without free apoB (control) showed a normal appearance
(Fig. 4A). The cells treated with free apoB showed morphological
Fig. 4. Changes in cellular morphology observed by differential interference-contrast
microscopy. J774 macrophages were incubated for 6 h at 37 °C with 0.5 mM NaDC (A),
0.5 mM NaDC and 50 μg/ml free apoB (B), 0.5 mM NaDC and 50 μg/ml LDL-apoB (C), or
0.5 mM NaDC and 50 μg/ml apoA-I (D). The bar represents 10 μm.
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cells treated with LDL-apoB or apoA-I had the same appearance as
control cells (Fig. 4C and D). Very similar results were obtained in
HepG2 cells and CHO cells (data not shown). We concluded that free
apoB, but not apoA-I or LDL-apoB, has cytotoxicity to various types of
cells.
3.3. Apoptosis induced by free apoB
To characterize whether the cell death resulting from free apoB
treatment was caused by the induction of apoptosis, we measured
caspase-3 activity in J774 macrophages. Caspase-3 is a key effecter
caspase activated by several independent pro-apoptotic mechanisms,
and its activity is a good integral indicator of apoptosis [27]. As shownFig. 5. Caspase-3 activation induced by free apoB. J774 macrophages were incubated for
3 h at 37 °C in the absence (control), presence of 0.5 mM NaDC, or presence of 0.5 mM
NaDC and 20 μg/ml free apoB. Results are expressed as the percentage of caspase-3
activity measured in control cells. Each bar represents the mean±S.E. of three
measurements. ⁎Pb0.05, signiﬁcantly different from the caspase-3 activity in control
cells. #Pb0.05, signiﬁcantly different from the caspase-3 activity in the presence of
0.5 mM NaDC.in Fig. 5, caspase-3 activity was elevated in J774 macrophages
incubated with 20 μg/ml free apoB and 0.5 mM NaDC, but not in
cells incubated with 0.5 mM NaDC in the absence of free apoB.
In addition, apoptosis was also assessed by annexin V binding to
the surface of J774 macrophages. The annexin V binding method
detects phosphatidylserine exposure on the cell surface, which is
employed as an early marker of apoptosis. Necrotic cells also expose
phosphatidylserine. PI exclusion is used to differentiate between
apoptotic and necrotic cells. Necrotic cells, but not apoptotic cells, are
stained with PI due to the loss of membrane integrity. Apoptotic cells
are annexin V positive and PI negative, while necrotic cells are annexin
V positive and PI positive. After the incubation of J774 macrophages
with 20 μg/ml free apoB and 0.5 mM NaDC, the percentage of annexin
V positive and PI negative cells was markedly increased, while that of
annexin V positive and PI positive cells was slightly, but not
signiﬁcantly, increased (Fig. 6). The percentage of annexin V positive
and PI negative cells was not increased in the cells incubated with
0.5 mM NaDC in the absence of free apoB. These results indicated that
free apoB induces apoptosis in J774 macrophages.
3.4. Free apoB binding/uptake by J774 macrophages
Next, we explored whether free apoB is bound to and/or taken up
by J774 macrophages. Fig. 7 shows that the binding/uptake of free
apoB by J774 macrophages was 3.1-fold greater than that of LDL-apoB.
This result indicated that the binding/uptake of apoBwas promoted by
the dissociation of apoB from LDL particles.
3.5. Involvement of LDL receptor, HSPGs and SRA in free apoB binding/
uptake by J774 macrophages
To assess if known lipoprotein receptors on J774 macrophages are
responsible for the free apoB binding/uptake, we conducted some
experiments using inhibitors of lipoprotein receptors. LDL receptor
plays the major role in plasma LDL uptake. Lipoproteins bind to cell
surfaces through interactions with heparan sulfate proteoglycans
(HSPGs). HSPGs participate in lipoprotein uptake, either associating
with LDL receptor-related protein or acting alone as a receptor [28]. As
shown in Fig. 8, LDL-apoB signiﬁcantly inhibited the binding/uptake ofFig. 6. Increase in annexin V binding by free apoB. J774macrophages were incubated for
6 h at 37 °C in the absence (control), presence of 0.5 mM NaDC, or presence of 0.5 mM
NaDC and 20 μg/ml free apoB. The cells stained by annexin V-ﬂuorescein and PI were
observed using a ﬂuorescence microscope. Numbers of annexin V positive/PI negative
and annexin V positive/PI positive cells from 8 different ﬁelds were quantiﬁed.
Experiments were repeated 3 times. Each bar represents the mean±S.E. of three
experiments. ⁎Pb0.05, signiﬁcantly different from control cells. #Pb0.05, signiﬁcantly
different from the cells in the presence of 0.5 mM NaDC.
Fig. 9. LDH release from cells induced by free apoB in the presence of inhibitors for
cellular binding/uptake. J774 macrophages were incubated for 6 h at 37 °C with 0.5 mM
NaDC and 20 μg/ml free apoB in the absence (control) or presence of 100 μg/ml LDL-
apoB, 100 μg/ml heparin, 20 μg/ml control IgG, or 20 μg/ml anti-SRA IgG. Each per-
centage represents the mean±S.E. of three measurements. The absence of an error bar
signiﬁes an S.E. value smaller than the graphic symbol.
Fig. 7. Binding/uptake of LDL-apoB and free apoB by J774 macrophages. J774
macrophages were incubated for 2 h at 37 °C with 0.5 mM NaDC in the presence of
10 μg/ml LDL-apoB or 10 μg/ml free apoB. Each bar represents the mean±S.E. of three
measurements. ⁎Pb0.05, signiﬁcantly different from LDL-apoB.
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selectively blocks ligand binding to heparan sulfate side chains of
HSPGs but not lipoprotein binding to the members of the LDL receptor
family or other lipoprotein receptors [29–32]. Heparin also markedly
reduced the binding/uptake of free apoB (Fig. 8).
To examine the involvement of SRA and CD36 in the free apoB
binding/uptake by J774 macrophages, we tested the binding/uptake in
the presence of antibodies against either SRA or CD36, which are
known to block the uptake of modiﬁed LDL [33,34]. The anti-SRA IgG
markedly inhibited the binding/uptake of free apoB compared with
control IgG, whereas the antibody against CD36 had no effect on the
binding/uptake of free apoB by J774 macrophages (Fig. 8). Thus, LDL
receptor, HSPGs and SRA are involved in the binding/uptake of free
apoB by J774 macrophages.
3.6. Effect of inhibitors for free apoB binding/uptake on cell viability
To investigate the correlation between the free apoB binding/
uptake through the receptors and the cytotoxic effect of free apoB, we
measured the LDH release after incubation with free apoB in the
presence of inhibitors for the binding/uptake (Fig. 9). LDL-apoB and
heparin had no signiﬁcant effect on the LDH release induced by freeFig. 8. Effects of LDL-apoB, heparin, and antibodies against SRA or CD36 on the binding/
uptake of free apoB by J774 macrophages. J774 macrophages were incubated for 2 h at
37 °C with 0.5 mM NaDC and 10 μg/ml free apoB in the absence (control) or presence of
100 μg/ml LDL-apoB, 100 μg/ml heparin, 20 μg/ml control IgG, 20 μg/ml anti-SRA IgG,
20 μg/ml control IgA or 20 μg/ml anti-CD36 IgA. Results are expressed as a percentage of
the respective apoB binding/uptake measured in control cells. Each bar represents the
mean±S.E. of three measurements. ⁎Pb0.05, signiﬁcantly different from control.
#Pb0.05, signiﬁcantly different from control IgG.apoB. There was no difference in the free apoB-induced LDH release in
the presence of control IgG or anti-SRA IgG. These results suggest that
the cytotoxic effect of free apoB may be due to non-speciﬁc binding
to the plasma membrane, rather than the binding/uptake mediated
by the lipoprotein receptors.
3.7. Effect of free apoB on membrane integrity
To estimate the effect of free apoB on the integrity of the lipid
bilayer, we examined the leakage of calcein from LUV. Free apoB, LDL-
apoB or apoA-I was added to the calcein-containing LUV, and the
ﬂuorescence intensity was measured at 520 nm. Free apoB induced
extreme leakage of calcein just after addition (Fig.10). In contrast, LDL-
apoB or apoA-I did not cause the leakage. These results suggested that
free apoB, but not LDL-apoB or apoA-I, disrupted the structure of the
lipid bilayer.
3.8. Effect of free apoB on intracellular Ca2+ concentration
To evaluate whether free apoB disrupts the membrane structure of
living cells, we observed the change in intracellular Ca2+ concentrationFig. 10. Leakage of calcein from PC LUV induced by free apoB. LUV of 1 mM PC were
exposed to 50 μg/ml free apoB, 50 μg/ml LDL-apoB, or 50 μg/ml apoA-I in the presence of
0.5 mM NaDC. The ﬂuorescence intensity of calcein was monitored at 37 °C. 100%
leakage was obtained in the presence of 1% Triton X-100. Average results are from three
independent experiments for each sample.
Fig. 11. Change in intracellular calcium concentration by free apoB. J774 cells containing
Fura-2 were exposed to 50 μg/ml free apoB, 50 μg/ml LDL-apoB, or 50 μg/ml apoA-I in
the presence of 1.8 mM Ca2+ (A) or 0.3 mM EGTA (B) at 37 °C. Before adding free apoB,
300 nM thapsigargin was incubated with the cells for 3 min. The arrows indicate the
time-point at which free apoB, LDL, apoA-I or thapsigargin was applied to the cells. The
data were shifted upward to avoid overlap.
Fig. 12. Change in intracellular Ca2+ concentration by free apoB in the presence of
inhibitors for cellular binding/uptake. J774 cells containing Fura-2 were exposed to
50 μg/ml free apoB in the presence of 100 μg/ml LDL-apoB, 100 μg/ml heparin, 20 μg/ml
control IgG, or 20 μg/ml anti-SRA IgG at 37 °C. Before adding free apoB, each inhibitor for
free apoB binding/uptake was incubated with cells for 3 min. The arrows indicate the
time-point at which free apoB, LDL-apoB, heparin, control IgG, or anti-SRA IgG was
applied to the cells. The data were shifted upward to avoid overlap.
2600 S. Morita et al. / Biochimica et Biophysica Acta 1778 (2008) 2594–2603using a Ca2+ indicator, Fura-2. Fura-2-loaded cells were suspended in
buffer containing either Ca2+ or EGTA, a calcium chelating agent, to
monitor inﬂux or efﬂux of Ca2+ through cell membrane, respectively.
In the presence of Ca2+, free apoB increased the intracellular Ca2+ level,
while LDL-apoB and apoA-I did not (Fig.11A). On the other hand, in thepresence of EGTA, free apoB decreased the intracellular Ca2+ level
(Fig. 11B). These results suggest that free apoB disrupts cell
membranes and causes Ca2+ inﬂux or efﬂux in the presence or
absence of extracellular Ca2+, respectively. Thapsigargin, an inhibitor
of endoplasmic reticulum Ca2+ ATPase, raises the cytosolic Ca2+
concentration and depletes intracellular Ca2+ stores [35]. Treatment
with thapsigargin had no inhibitory effect on the free apoB-induced
Ca2+ inﬂux and efﬂux (Fig. 11A and B), suggesting that Ca2+ derived
from intracellular stores is not involved in the change in intracellular
Ca2+ concentration induced by free apoB.
3.9. Relationship between free apoB binding/uptake and Ca2+ inﬂux
We investigated the effect of free apoB binding/uptake on Ca2+
inﬂux using anti-SRA IgG, LDL-apoB and heparin. Even after treatment
with the inhibitors that were shown to inhibit apoB binding/uptake
(Fig. 8), free apoB increased intracellular Ca2+ concentration (Fig. 12).
2601S. Morita et al. / Biochimica et Biophysica Acta 1778 (2008) 2594–2603These results indicate that the free apoB binding/uptake mediated by
the receptors does not participate in the apoB-induced Ca2+ inﬂux.
4. Discussion
In this report, we used lipid-free apoB solubilized in NaDC as a
model for denatured apoB. NaDC is reasonable detergent to solubilize
free apoB because it is weakly ionic detergent with adequate critical
micellar concentration to solubilize intrinsic membrane proteins [19].
Gantz et al. demonstrated that apoB in NaDC appeared to be long, thin,
apparently ﬂexible molecules when negatively stained [36]. With
negative staining, the apoB molecules have a mean length of 650 Å
[36]. Walsh and Atkinson reported that apoB in NaDC has the same
percentage of α-helices and β-sheets as apoB in LDL over the
temperature range 5–30 °C, but that the secondary structure of apoB
in NaDC is altered between 30 and 50 °C, with a decrease in the
amount of β-sheet and a concomitant increase in random coil [37,38].
In this study, however, we showed that free apoB in NaDC had lower
α-helix content than LDL-apoB at 37 °C (Table 1). The small change in
the CD spectrum of free apoB (Fig. 1) was very similar to that of heated
LDL [21]. By heating to 100 °C, LDL particles are converted into small
LDL-like particles and large lipid droplets along with thin strands that
closely resemble NaDC-solubilized apoB suggesting apoB dissociation
[21]. Heating to 115 °C leads to nearly complete conversion of LDL
particles into large aggregated lipid droplets similar to the extra-
cellular lipid deposits in atherosclerotic plaques [21]. The heat-
induced LDL size reduction and lipid droplet formation may resemble
metabolic LDL transformations in normal and in atherosclerotic states
[21].
In the process of atherogenesis, LDL particles are modiﬁed and
accumulated in the arterial walls [1,2]. There are several modifying
substances for circulating and subendothelial LDL, such as proteolytic
enzymes [39], sphingomyelinase [40,41], phospholipase A2 [42,43]
and pro-oxidative agents [44]. Modiﬁed LDL exerts biological effects
on arterial cells and macrophages, including the induction of cell
death, apoptosis [3,4]. The modiﬁcation of LDL may lead to a
conformational change in apoB. The secondary structure and
conformation of apoB in LDL are imposed by lipid-protein interactions
and dynamics [45]. Following an alteration in thewater-lipid interface
as a result of oxidation of lipids, the structure becomes destabilized
and apoB could misfold [45]. A previous study indicated that the
secondary structure and conformation of apoB are severely altered in
electronegative LDL, a fraction of oxidatively modiﬁed LDL isolated in
vivo [22]. Higher β-strand structural content and unfolding propor-
tionate to the loss of the α-helical structure of apoB in electronegative
LDL have been demonstrated by CD spectropolarimetry [43].
Decreased CD signal of apoB and shorter tryptophan ﬂuorescence
lifetime are observed for oxidized LDL, indicating that the secondary
structure is changed, and that apoB unfolds into a conformation in
which tryptophan residues are more exposed to water following
oxidation [24]. It has been proposed that misfolded apoB that
accumulated and aggregated in atherosclerotic lesions could induce
cytotoxic effects [45]. It is conceivable that apoB was dissociated
partially or entirely from the LDL particle and folded incorrectly as a
result of several modiﬁcations in arterial walls, which may contribute
to the development of atherosclerosis.
In the present study, we showed that lipid-free apoB had
cytotoxicity to J774 macrophages, CHO cells and HepG2 cells (Figs. 3
and 4). LDL-apoB, namely apoB in the lipid-bound state, exhibited no
cytotoxic effect (Figs. 3 and 4). Lipid-free apoA-I showed no cytotoxic
effect (Figs. 3 and 4). ApoA-I is an exchangeable plasma apolipoprotein
mainly consisting of amphipathicα-helices [46]. Taken together, these
ﬁndings suggest that the amphipathic β-sheet domains of apoB in the
lipid-free state may contribute to the cytotoxic effect.
It has been reported that LDL receptor binding sites exist in the α3
domain of apoB [47]. HSPGs act as potential receptors for atherogeniclipoproteins or facilitate their uptake by ligand transfer to LRP [28].
ApoB has several heparin-binding sites [48] and LDL receptor binding
sites also interact with proteoglycans [49]. In addition to heparin, LDL-
apoB may partly inhibit the ligand binding to HSPGs. LDL-apoB and
heparin signiﬁcantly inhibited the binding/uptake of free apoB (Fig. 8),
suggesting that these binding sites of free apoB interact with LDL
receptor and HSPGs. CD spectral measurement revealed that the
secondary structure was well preserved in free apoB solubilized by
NaDC (Fig. 1 and Table 1). The structures of LDL receptor binding sites
and heparin-binding sites in free apoB may be maintained and can
interact with LDL receptor and HSPGs. Modiﬁed LDL, such as oxidized
LDL, acetyl LDL or malondialdehyde LDL, can bind to SRA [50,51].
Abundant expression of SRA is seen in macrophages in early
atherosclerotic lesions [52]. Anti-SRA IgG markedly reduced the
binding/uptake of free apoB by J774 macrophages (Fig. 8), although
there was only a slight decrease in the LDL-apoB binding/uptake in the
presence of anti-SRA IgG (data not shown), suggesting that free apoB
can be recognized by SRA similarly to modiﬁed LDL.
We found, however, that the binding/uptake of free apoB was not
involved in cytotoxicity (Fig. 9). Free apoB was revealed to have the
ability to disrupt the lipid bilayer (Fig. 10) and cellular membrane (Fig.
11). A free apoB-induced increase in the intracellular Ca2+ concentra-
tion was brought about by inﬂux of extracellular Ca2+, but not by
calcium mobilization from intracellular Ca2+ stores (Fig. 11B).
Furthermore, the inhibitors for binding/uptake of free apoB did not
show any inhibitory effects on the membrane disruption (Fig. 12).
Taken together, free apoB is considered to play a critical role in
cytotoxicity at the cellular surface. It has long been known that an
increase in intracellular Ca2+ can activate cytotoxic mechanisms that
result in perturbations of cellular structure and function [53].
Therefore, our study suggests that Ca2+ ﬂowing into cells by
membrane disruption with apoB can trigger cell death. We further
demonstrated that free apoB led to apoptosis in J774 macrophages
(Figs. 5 and 6). In addition, the apoB-induced membrane disruption
should evoke the inﬂux and efﬂux of various molecules other than
intracellular Ca2+, since apoB can leak calcein (MW 622.53) from a
model membrane. Thus, other factors that induce apoptosis may
transit through the disrupted membrane.
The lipid-binding property of apoB is ascribed to a series of
amphipathic α-helical and β-strand domains arranged in the
following order: NH2-βα1-β1-α2-β2-α3-COOH [54]. The amphipathic
α-helices of the βα1 domain are class G⁎, and the βα1 domain
represents a globular region [54]. The amphipathicα-helices of theα2
and α3 domains are mostly class A and Y, which are found in
exchangeable apolipoproteins [54]. It is suggested that the amphi-
pathic β-strands are the anchors that keep apoB bound to the
lipoprotein surface [55,56]. This high afﬁnity of apoB for lipids may
promote the binding of free apoB to the plasmamembrane of the cells.
ApoB-containing lipoprotein assembly requires the phospholipid
transfer activity of microsomal triglyceride transfer protein [57]. In
the absence of microsomal triglyceride transfer protein, apoB folds
incorrectly and undergoes proteasomal degradation. Therefore, the
binding of free apoB to the plasma membrane could conceivably lead
to misfolding and membrane disruption.
Ursini et al. proposed that the misfolding of apoB, its aggregation,
resistance to proteolysis, and cytotoxicity are common motifs shared
by modiﬁed LDL and amyloidogenic proteins [45]. The oxidation of
LDL generates characteristic amyloid-like structures that are recog-
nized by macrophages [58]. Asatryan et al. observed strong immunor-
eactivity of an electronegative LDL subfraction with an amyloid
oligomer-speciﬁc antibody [43]. Parasassi et al. have recently
predicted that a structure in the α2 domain is highly prone to a
conformational switch from a native α-helical arrangement toward
cross-β aggregation with other protein molecules [26]. The ability of
apolipoproteins to form amyloid has been reported for various full-
length andmutant derivatives of apoA-I, apoA-II, apoA-IV, apoC-II and
2602 S. Morita et al. / Biochimica et Biophysica Acta 1778 (2008) 2594–2603apoE [59–66]. ApoC-II amyloid ﬁbrils bind to CD36 and initiate
macrophage inﬂammatory responses similar to those induced by β-
amyloid [67]. However, our data indicated that CD36 was not involved
in the uptake of free apoB by J774 macrophages (Fig. 8).
In conclusion, free apoB had cytotoxic effects on several types of
cells. Although free apoB was bound to and/or taken up by cells
through LDL receptor, HSPGs and SRA, this event was not involved in
the cytotoxic effects. Because of the physicochemical property, free
apoB interacts with the plasma membrane of cells, disturbs its
structure, and triggers apoptosis. Misfolded apoB accumulated in
atherosclerotic lesionswould lead to cell death.We demonstrated that
apoB itself has an ability to induce apoptosis, in addition to other lipid
component in modiﬁed LDL. Therefore, apoB may play an important
role in the development of atherosclerosis.
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